SARS-Cov-2 infection disease
Conditions
Interventions
Treatment Group:Renshen Fuling Decoction
Placebo:Renshen Fuling Decoction Simulant
Sponsors
The Second Affiliated Hospital of Zhejiang Chinese Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Severe inpatients who meet the diagnostic criteria for novel coronavirus infection; 2. Conforming to the diagnostic criteria of epidemic virus closed lung syndrome; 3. Age >= 18 years old; 4. Participate voluntarily, understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. patients with severe liver function impairment and active liver disease Andor alanine transferase or L-Aspartic Acid transferase levels >= 5 times the upper limit of normal; 2. the patients who received hemodialysis or EGFR < 30ml/min/1.73 m2(according to the MDRD equation) ; 3. patients with other severe organ failure or mental diseases, patients with severe depression, alcohol dependence or history of drug abuse; 4. allergic constitution or previous allergic to multiple drugs, or to the ingredients in the research drug allergy; 5. patients with a history of cancer or present cancer, or with precancerous lesions confirmed by pathological examination; 6. pregnant and lactating women and those who are preparing to give birth during or within 3 months after the cessation of medication; 7. patients who were considered not suitable to participate in this study by other investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All-cause mortality (%) and the time from enrollment to death (d) on the 14th and 28th days;Rate of conversion from severe to critical within 14 days (%);Rate of mechanical ventilation with endotracheal intubation in severe patients (%) and time from admission to endotracheal intubation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate and time of weaning mechanical ventilation;Time of nucleic acid turning negative;Improvement of TCM syndrome;Improvement of lung HRCT score; | — |
Countries
China
Contacts
Public ContactLei Dong
The Second Affiliated Hospital of Zhejiang Chinese Medical University/ Zhejiang Chinese Medical University
Outcome results
None listed